Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide dosing for weight loss follows a specific titration protocol that typically starts at 0.25 mg weekly and increases every four weeks. Clinical trials show that gradual dose escalation reduces nausea and improves tolerability while achieving sustainable weight reduction. PlexusDx helps patients navigate this process with precision dosing tailored to their body's response.
Understanding Semaglutide Dosing Tiers and Titration
Semaglutide works through a dose-escalation model designed to help your body adapt to the medication gradually. The standard titration schedule spans 16 weeks, starting with 0.25 mg once weekly, then progressing to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the maintenance dose. This careful progression allows your gastrointestinal system to adjust and reduces the likelihood of severe side effects like nausea or constipation.
Not every patient reaches the maximum 2.4 mg dose—many find their optimal response at lower or intermediate levels. Your healthcare provider assesses your weight loss progress, tolerance, and metabolic markers at each step to determine whether to continue advancing your dose. Some individuals achieve meaningful results at 1.7 mg and choose to remain stable there, while others benefit from progressing to the full 2.4 mg strength. The key principle is finding your personal therapeutic dose, not automatically going to the highest level.
How Your Body Responds at Each Semaglutide Dose Level
The 0.25 mg starting dose activates GLP-1 receptors in your brain and gut with minimal systemic exposure, helping suppress appetite without overwhelming your system. At this level, many patients notice a subtle reduction in food cravings and improved meal satisfaction, though dramatic weight loss is not yet expected. The primary goal of weeks 1–4 is establishing tolerance, allowing you to assess how your body handles the medication before increasing strength.
Advancing to 0.5 mg in week 5 typically produces noticeable appetite suppression and early weight loss in most patients. By 1.0 mg (week 9), weight reduction accelerates for many individuals as GLP-1 signaling becomes more robust, affecting both hunger signals and blood sugar stability. The 1.7 mg and 2.4 mg doses represent the therapeutic plateau where maximum GLP-1 receptor engagement occurs, producing the most significant reductions in body weight and improvements in metabolic health markers documented in clinical trials.
Factors That Influence Your Ideal Semaglutide Dose
Your genetics play a significant role in how effectively semaglutide works at each dose level. Variations in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) influence your receptor sensitivity and peptide responsiveness. PlexusDx Precision Peptide Genetic Test maps these pathways across 49 peptides and 150+ genetic insights, revealing your personal predisposition to GLP-1 sensitivity and helping providers select the most effective starting strategy.
Body composition, baseline metabolic rate, and concurrent medications all affect semaglutide dosing decisions. Patients with higher insulin resistance may benefit from advancing the dose more quickly to achieve metabolic benefits, while those with slower gastric emptying might need extended time at each level. Age, kidney function, and other chronic conditions also inform personalized dosing protocols that optimize results while minimizing unwanted gastrointestinal effects.
PlexusDx Semaglutide Injection: Pricing and Access
PlexusDx Compounded Semaglutide Injection starts at $149 per month across all dose levels, with no additional costs as your dose increases. This flat monthly rate removes barriers to accessing full-strength treatment, ensuring patients can reach their therapeutic dose without financial hesitation. PlexusDx serves all 50 states, requires no insurance, and accepts HSA and FSA contributions, making personalized semaglutide therapy accessible to motivated individuals nationwide.
Medications are prepared by licensed 503A compounding pharmacies under strict quality standards, ensuring pharmaceutical-grade purity and potency. PlexusDx pairs semaglutide dosing with optional Precision Peptide Genetic Testing ($99 add-on after your first month) to refine your protocol based on your unique genetic architecture. This integration of precision genetics and transparent flat pricing empowers patients to achieve sustainable weight loss without surprise costs or insurance delays.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the standard starting dose of semaglutide for weight loss?
The standard starting dose is 0.25 mg injected subcutaneously once weekly. This low dose allows your body to adapt to GLP-1 receptor activation while minimizing nausea and other side effects. Most patients advance to the next dose level after four weeks of tolerating the current strength.
How long does it take to reach the maximum semaglutide dose of 2.4 mg?
The full titration schedule typically spans 16 weeks, with dose increases every four weeks: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), and 2.4 mg (week 17 onward). However, some patients reach their optimal dose earlier and remain stable at lower levels based on their individual response.
Does my semaglutide price increase as my dose goes up?
No. PlexusDx Compounded Semaglutide Injection maintains a flat monthly rate of $149 regardless of your dose level—your dose may need to go up, but your price won't. This pricing structure ensures affordability as you reach your therapeutic dose.
What happens if I cannot tolerate a higher semaglutide dose?
If side effects become problematic, your healthcare provider can extend the time at your current dose, pause advancement temporarily, or recommend staying at a lower therapeutic level. Many patients achieve excellent weight loss and metabolic improvements without reaching 2.4 mg, and staying stable at 1.0–1.7 mg is a valid treatment strategy.
Can the PlexusDx Precision Peptide Genetic Test help optimize my semaglutide dosing?
Yes. The genetic test identifies variants in GLP1R (rs6923761) and GIPR (rs1800437) that predict your sensitivity to GLP-1 peptides, along with FTO and MC4R markers affecting metabolic predisposition.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Relieve Constipation on GLP-1: Effective Strategies for Comfort
Are Semaglutide Tablets as Effective as Injections for Weight Loss?